Drug Trial Radar · NCT06525935
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
469
Actual
Start
Aug 16, 2024
Primary completion
Dec 8, 2025
Study completion Dec 8, 2025
Sponsor
- Lead sponsor
- Carmot Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Hoffmann-La Roche
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.
Conditions
- Obesity
- Overweight
Interventions
PlaceboDrug
Placebo will be volume- matched and administered subcutaneously (SC) once weekly.
EnicepatideDrug
Enicepatide will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Body Weight from Baseline to Week 48Time frame: Baseline to Week 48
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama
Central Alabama Research
Homewood, Alabama
The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health
Mesa, Arizona
Amicis Research Center - Anaheim
Anaheim, California
Ark Clinical-Fountain Valley
Fountain Valley, California
Ark Clinical Research - Long Beach
Long Beach, California
Velocity Clinical Research - Los Angeles
Los Angeles, California
Infinity Clinical Research
Norco, California
Amicis Research Center
Northridge, California
Prospective Research Innovations Inc.
Rancho Cucamonga, California
Orange County Research Center
Tustin, California
Amicis Research Center - West Hills
West Hills, California
Tampa Bay Medical Research, Inc.
Clearwater, Florida
Progressive Medical Research
Port Orange, Florida
Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
Louisville, Kentucky
The Center for Pharmaceutical Research
Kansas City, Missouri
Mercury Street Medical Group
Butte, Montana
Neurobehavioral Research, Inc. (NBR)
Cedarhurst, New York
Lucas Research, Inc
Morehead City, North Carolina
Velocity Clinical Research - Cincinnati
Cincinnati, Ohio
Velocity Clinical Research, Providence
East Greenwich, Rhode Island
Tribe Clinical Research
Greenville, South Carolina
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee
Clinical Research Associates, Inc.
Nashville, Tennessee
Texas Diabetes & Endocrinology, P.A.
Austin, Texas
Apex Mobile Clinical Research
Bellaire, Texas
Velocity Clinical Research - Dallas
Dallas, Texas
FutureSearch Trials of Dallas, LLC
Dallas, Texas
University of Texas Southwestern
Dallas, Texas
Pinnacle Clinical Research
San Antonio, Texas
Elevate Clinical
Seabrook, Texas
Impact Research Institute
Waco, Texas
Chrysalis Clinical Research
St. George, Utah
National Clinical Research - Richmond, Inc
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.